Roche launches new therapy Emicizumab for Hemophilia A patients
This opens up treatment options for people living with Hemophilia A with factor VIII inhibitors and is the first prophylaxis (preventive) therapy to significantly reduce treated bleeds, administered weekly subcutaneously (under the skin) rather than intravenously